RAAV-Olig001-ASPA ( DrugBank: rAAV-Olig001-ASPA )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 307 | Canavan disease | 1 |
307. Canavan disease
Clinical trials : 6 / Drugs : 11 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 2
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04833907 (ClinicalTrials.gov) | April 1, 2021 | 24/3/2021 | rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease | Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan Disease | Canavan Disease | Drug: rAAV-Olig001-ASPA;Drug: Levetiracetam;Drug: Prednisone | Myrtelle Inc. | NULL | Active, not recruiting | 3 Months | 60 Months | All | 24 | Phase 1/Phase 2 | United States |